Comparison of effectiveness and complication of rituximab and fingolimod in improvement disability motio
Phase 3
- Conditions
- Multiple Sclerosis.Multiple sclerosis
- Registration Number
- IRCT20130812014333N125
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 36
Inclusion Criteria
Age between 18-55 years
Negative pregnancy test in women of reproductive age
At least one relapse in the past year, despite first-line Dimethyltryptamine treatment
At least two relapse in the past two years, despite First-line Dimethyltryptamine treatment
Active lesions (a new Type2 (T2) or Gadolinium(GAD) enhancement) and having two or more attacks in the past year despite the first-line treatment in recurrent patients
Active lesions (new T2 lesions or GAD enhancement) and attack in patients who have the progressive form of illness
Exclusion Criteria
Acute or chronic bacterial, viral or fungal infection
Sensitivity to drug
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disability motion. Timepoint: At the beginning of the study and one year after the study. Method of measurement: Base on Expanded Disability Scale Score(EDSS).;Medicine complications. Timepoint: Start and during treatment. Method of measurement: Doctor observation and asking from patient.;Relapse of the disease. Timepoint: Annually. Method of measurement: Diagnosis of the doctor.
- Secondary Outcome Measures
Name Time Method